Skip to main content
. 2014 Oct 15;3(10):e141. doi: 10.1038/psp.2014.39

Figure 2.

Figure 2

Predicted therapeutic IC50 values. (a) For a range of gefitinib or cetuximab concentrations and 1.6 nmol/l EGF or amphiregulin (AR), the amount of steady-state phosphorylated epidermal growth factor receptor (EGFR) (pEGFR) was computed and normalized to the amount of pEGFR in the absence of therapeutic. (b) From the data shown in panel (a), gefitinib and cetuximab IC50 values were calculated for each ligand/therapeutic pair. (c and d) Calculations in panels (a) and (b) were repeated for 160 nmol/l AR and compared to results for 1.6 nmol/l EGF.